

# **LM strategy from MITO registry**

**Ogaki Municipal Hospital**

**Kensuke Takagi**

# Agenda

---

**□ Introduction**

**□ MITO Registry**

**□ Left Main PCI strategy**

# Agenda

---

**□ Introduction**

**□ MITO Registry**

**□ Left Main PCI strategy**

# Introduction: LMT-PCI

**Non optimal strategy is associated with increased risk of Cardiac death.**

*JACC: Cardiovascular Interventions, 2016, 2086–2093*

Perfect

**Most of LM bifurcation is not strongly recommended.**

*ESC2018, JCS2010, ACC/AHA2017*

vs. CABG

Guideline

**LITA-LAD patency is more than 95% in 10-years.**

*Ann Thorac Surg. 2005 Feb;79(2):544-51;*

# Introduction: LCx

Most of ISR located in LCx ostium.

Achilles

*Takagi et al. Circ Cardiovasc Interv. 2012;109:1244-1249.*

*Ojeda, et al. JACC Interv 2014*

Benign

Most of bifurcation strategy is not simple.

Complicated

Stenosis of LCx had a small impact on long-term mortality.

*Takagi et.al Catheter Cardiovasc Interv. 2013*


*Mitomo et al. Int J Cardiol. 2017 Oct 15;245:77-82.*

*Ojeda, et al. JACC Interv 2014*

# Introduction: Territory of LCx

- ✓ Balloon Size 3.5mm<sub>≥</sub>: **10.4%** (n-579)
- ✓ Vessel diameter 3.0mm<sub>≥</sub>: **15.4%** (n-862)
- ✓ Vessel diameter 3.0mm<sub>></sub> & TBL: **9.0%**(n-862)

Mito Registry



Eur. J. Anat. 22 (4): 355-365 (2018)

# Agenda

---

□ Introduction

□ **MITO Registry**

□ Left Main PCI strategy

# MITO and New-Tokyo Registry

- #8 Rota
- #9 LM Optimal stenting
- #10 OCT: mechanism of ISR
  - OCT: effectiveness in LM



**MITO LM Registry n=1029 patients**

**1st DES  
N=765**

**2nd DES  
N=264**

- #1 LM-ISR
- #2 LM MB restenosis
- #3 Trifurcation
  - RCA-CTO
- #4 LM-LCx stenting
  - Ostial
- #5 Renal dysfunction
  - Gender
- #6 1-stent vs. 2-stent
- #7 Mini vs. cullote
  - TAP
  - **Cross-over with KBT**



*Naganuma.T*



*Kawamoto.T*

*Mitomo.S*

*Watanabe.Y*



# #1 Every MITO findings began...

Takagi et al. *Circ Cardiovasc Interv.* 2012;109:1244-1249.


## Baseline Angiographic Characteristics in UDLM Patients According to Stent Strategy

Patients: n (%)	All patients (n=474)	1-Stent Strategy (n=280)	2-Stent Strategy (n=194)	p-value
LM+ 3VD	191 (40.3)	98 (35.0)	93 (47.9)	0.006
Stenosis of LCx >75%	171 (36.1)	67 (23.9)	104 (53.6)	0.001
Stenosis Length of LCx >10mm	94 (19.8)	36 (12.9)	58 (29.9)	0.001
True-Bifurcation (Medina 111, 101, 011)	292 (61.6)	133 (47.5)	159 (82.0)	0.001
IABP	71 (15.0)	27 (9.6)	44 (22.7)	0.001
Angiographic follow-up	416 (87.8)	244 (87.1)	172 (88.7)	0.67



# #1 ISR located in ostial LCx following LM-PCI

Takagi et al. *Circ Cardiovasc Interv.* 2012;109:1244-1249.

## Mito registry in 1<sup>st</sup> DES



## POBA vs. DES



Supportive paper


Ojeda et al. *JACC Cardiovasc Interv* 2014  
[KIM et al. \*JACC Cardiovasc Interv.\* 2012 Jul;5\(7\):708-17.](#)

# #2 LCxos-ISR has a small impact on long-term mortality

Takagi et.al Catheter Cardiovasc Interv. 2013

## 937 Distal LM from MITO registry

Cumulative survival free from Cardiac death



Unpublished data

Supportive paper

Ojeda et al. JACC Cardiovasc Interv 2014

JCR in Busan

# #2 LM-LAD-ISR has a impact on long-term mortality

Takagi et.al Catheter Cardiovasc Interv. 2013 Sep 2


## Predictors of LMMB-ISR

	Univariable HR (CI)	P Value	Coxadjusted HR (CI)	P Value
Calcification	2.114 (1.085-4.121)	0.03	2.284 (1.165-4.475)	0.02
True-bifurcation	2.764 (1.344-5.668)	0.01	2.331 (1.117-4.862)	0.02
IDDM	2.742 (1.234-6.092)	0.01	2.259 (1.007-5.068)	0.05
Post MLD	0.568 (0.346-0.932)	0.03	0.611 (0.364-1.026)	0.06
<b>Post dilatation</b>	<b>0.43</b> (0.23-0.81)	0.01	<b>0.55</b> (0.28-1.07)	0.08
<b>Full cover</b>	<b>0.41</b> (0.24-0.71)	0.001	<b>0.61</b> (0.34-1.09)	0.09
IABP	2.115 (1.126-3.971)	0.02		
3 VD	1.750 (1.015-3.016)	0.04		
Dialysis	2.760 (0.993-7.670)	0.05		
2-stent strategy	1.651 (0.957-2.848)	0.07		

# #2/#9 Full cover + POT reduce MB-ISR

Takagi et.al Catheter Cardiovasc Interv. 2013 Sep 2 Cardiovasc Revasc Med. 2016 Sep 4


Not necessary in case of IVUS showing > 30% stenosis and long ostial LM




# #5/#8 HD and calcified LM are associated with poor outcomes...

*Yabushita, Takagi et al. Circ J. 2014;78(8):1867-72 Takagi et al. Int J Cardiol. 2014 Dec 20;177(3):1131-3.*

## New-Tokyo and MITO registry in HD



non-HD patients (n=51)	2.1%
HD patients (n=13)	46.2%
MI	4.7%
Definite/Probable ST	6.1%



*Yabushita, Takagi et al. Circ J. 2014;78(8):1867-72  
Takagi et al. Int J Cardiol. 2014 Dec 20;177(3):1131-3.*

## ROTATE registry 86 severe **calcified** UDLM patients


- definite/probable ST **3.9%** in LM vs. 0.8% in non-LM

*Lelasi, Kawamoto et al. Am J Cardiol. 2017 May 1;119(9):1331-1337.*

# #4 LM-LCx Stenting is not acceptable for medina 001.


Naganuma T et al. Catheter Cardiovasc Interv. 2013

If we focus on TLR for restenosis at the ostium of the stented-branch...




Restenosis at the LCx-ostium in

Restenosis at the LAD-ostium in




Kaplan-Meier 3-year incidence curve of TLR for restenosis at the ostium of the stented-branch



Oviedo C, et al. Circ Cardiovasc Interv 2010

## #6 Cardiac death was quite low in 2-SS using Second-DES. However, LCx-ISR was still high.

- Device :  
First DES in 75%
- Procedure:  
KBT in 95%, POT in 65%, IVUS in 60%
- Technique:  
Crush series in 51%
- Patient Background:  
High SYNTAX in 30%, ESRD in 7%




The difference between 1-SS and 2-SS in the LM-PCI is associated with the high development of SB restenosis in 2-SS, which had little impact on long-term mortality.



*Takagi et al. Circ Cardiovasc Interv. 2016;Nov; 9 (11)*



# DK crush is better than 1-SS in TBLM



# LM patients usually categorized to mode-high bleeding risk




*NATSUAKI et al. J Am Heart Assoc. 2018 May 22;7(11)*

**At least 72.6% of the LM patients belongs to intermediate and high bleeding risk group by Paris Score.**

# #10 Suboptimal 2-SS increased risk of neointima hyperplasia in carina

Fujino et al. *Int J Cardiol.* 2016;219:285-92

## Unique vessel reaction at carina side after 2-stent LM PCI



Usually, there is little plaque accumulation at carina side, however there is NIH accumulation at carina side of LCX proximal after 2 stent technique. Why does it happen?

Fujino, Y., Nakamura, S, et al. *Int J Cardiol.* 2016:219:285-92.

# Suboptimal 2-SS increased risk of LSS

Courtesy of Dr. Y.Fujino

Favorable Culotte

Unfavorable Culotte

LMCA

LMCA

LAD

LAD

LCX

LCX

LCX ostium  
Without  
jailed struts

LCX ostium  
With jailed  
struts

LMCA

LAD


LAD

LCX

LMCA

LAD

08






**Is KBI not necessary in LM bifurcation?**



# Uncovered and Malapposed strut in LCx increased cardiac mortality




Failed lesions showed significantly greater prevalence of malapposition >20% of struts/section (65% vs. 13%,  $P < 0.01$ ), stent struts crossing an **ostial side branch >30% of the LCx** (48% vs. 13%,  $P < 0.01$ ) and **uncovered struts > 30%** (57% vs. 18%,  $P = 0.03$ ).


*Mori et al. International Journal of Cardiology 263 (2018) 9–16*

# Residual stent Strut led to Low Share stress in Carina


## Without stent





## Single stent <pre KBT>






## Single stent <post KBT>







E **LCXos Area 1.68mm<sup>2</sup>**






# # KBI is necessary in non true bifurcation LM

Watanabe et al. Under review

## Kaplan–Meier curve of TLR for LCXos according to KBT



# Agenda

---


□ Introduction

□ MITO Registry


□ Left Main PCI strategy


# The number of PCI in Ogaki Municipal Hospital

■ 2018   
 ■ 2017   
 ■ 2016   
 ■ 2015



# LM-PCI① 76y.o Male EF30%






# LM-PCI① Final Angiography

**Full cover, EES, POT, KBT, 3DOCT, re-POT**




# LM-PCI② 83y.o male Severe AS

**LAD FFR : 0.66**






LCx: Rota, CB, DCB







# LM-PCI② Final Angiography

Full cover, **EES**, **POT**, **KBT**, 3DOCT, **re-POT**





# LM-PCI③ Suboptimal Case

**Full cover, EES, POT, KBT, 3DOCT, re-POT**



# LM-PCI④ Suboptimal Case

**Full cover, EES, POT, KBT, 3DOCT, re-POT**



# Take home message

---

- ✓ **Current Guideline does not support LM-PCI for complex LM. Therefore, optimal result should be achieved in all the LM patients.**
- ✓ **The indication should be carefully considered using physiological assessment. Furthermore, optimal medication and CABG is sometimes good alternative option.**
- ✓ **Single stent is still gold standard in LM-PCI. Using imaging modality, POT, Full coverage and KBI could guarantee the quality of LM-PCI.**